U.S. Marijuana Reclassification Report Fuels 9.5% Jump in Tilray Shares
TLRY has more than doubled off its 52-week low of $3.507 on elevated volume (4.4× avg).
Summary
A report from Axios, cited by Dow Jones Newswires, indicating the Trump Administration may reclassify marijuana from Schedule I to Schedule III as soon as today, has sent Canadian cannabis stocks, including Tilray Brands, significantly higher. Tilray shares advanced by 9.5% on the news. This potential regulatory shift is a major industry-wide catalyst, distinct from Tilray's recent corporate finance activities like the $180 million ATM program and debt-for-equity exchanges. Reclassification would fundamentally alter the operating landscape for cannabis companies by potentially easing federal restrictions on banking, research, and interstate commerce. Traders will be closely watching for official confirmation and the specific details of any reclassification from the U.S. administration.
At the time of this announcement, TLRY was trading at $7.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $895.1M. The 52-week trading range was $3.51 to $23.20. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.